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Summary
Pituitary dysfunction is a recognised, but potentially 
underdiagnosed complication of traumatic brain 
injury (TBi). Post-traumatic hypopituitarism (PTHP) 
can have major consequences for patients physically, 
psychologically, emotionally and socially, leading to 
reduced quality of life, depression and poor rehabilitation 
outcome. However, studies on the incidence of PTHP 
have yielded highly variable findings. The risk factors and 
pathophysiology of this condition are also not yet fully 
understood. There is currently no national consensus for 
the screening and detection of PTHP in patients with 
TBi, with practice likely varying significantly between 
centres. in view of this, a guidance development group 
consisting of expert clinicians involved in the care of 
patients with TBi, including neurosurgeons, neurologists, 
neurointensivists and endocrinologists, was convened to 
formulate national guidance with the aim of facilitating 
consistency and uniformity in the care of patients with 
TBi, and ensuring timely detection or exclusion of 
PTHP where appropriate. This article summarises the 
current literature on PTHP, and sets out guidance for the 
screening and management of pituitary dysfunction in 
adult patients with TBi. it is hoped that future research 
will lead to more definitive recommendations in the form 
of guidelines.
DevelopmeNT of The guiDaNCe
aims of the guidance
There is currently no widely accepted standard 
as to which patients should be screened for pitu-
itary dysfunction following a traumatic brain 
injury (TBI). Several groups outside the UK have 
provided recommendations,1–3 but these lack 
uniformity with respect to the optimal methods 
and timing(s) of screening.
This document aims to provide guidance on 
(1) who, (2) when and (3) how to screen for and 
manage pituitary dysfunction, including post-trau-
matic hypopituitarism, in adult patients with TBI, 
to ensure uniformity of practice across the country. 
It is primarily targeted at neurosurgeons who deal 
with TBI on a regular basis, but may also be relevant 
to clinicians from other specialties, including inten-
sive care, surgery and medicine. It is anticipated 
that this will also form the basis for future updates 
of related recommendations when new evidence 
becomes available.
This document should be used as guidance only, 
and clinicians must continue to exercise their judge-
ment when deciding on the management plan for 
individual patients.
process of development
A guidance development group comprising expert 
clinicians involved in the care of patients with TBI, 
including neurosurgeons, neurologists, neuroin-
tensivists and endocrinologists, was convened to 
develop this guidance. An initial meeting was held 
in October 2014 at Robinson College, Cambridge, 
UK. A draft guidance was subsequently dissemi-
nated by e-mail to all group members, and revised 
through multiple iterations to achieve consensus. 
The final version of the document was approved by 
all members of the group.
levels of evidence and grading of 
recommendations
The types of evidence and grading of recommenda-
tions used in this guidance are in accordance with 
those set out by the Agency for Healthcare Policy 
and Research.4 5
iNTroDuCTioN
Traumatic brain injury (TBI) has an estimated inci-
dence of 235/100 000 per year based on a systematic 
review of epidemiological data from 13 European 
countries,6 and results in 300 000 hospitalisa-
tions annually in the USA.7 In England and Wales, 
1.4 million people attend the emergency depart-
ment with a recent head injury annually, resulting 
in approximately 200 000 admissions.8 TBI most 
commonly affects young adults and frequently 
results in devastating consequences, including loss 
of independence, unemployment and significantly 
reduced quality of life.
The reported prevalence of post-traumatic 
hypopituitarism (PTHP) differs significantly 
between studies. Reasons for this include differ-
ences in inclusion/exclusion criteria (eg, severity 
of TBI), variability in testing protocols (eg, use of 
static vs dynamic tests), timing(s) of assessment 
(acute vs later phases) and differing thresholds for 
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diagnosis of hormone deficiencies.9 10 A meta-analysis of 14 
studies reported the pooled prevalence of PTHP to be 27.5%.11 
When classified according to the severity of TBI based on the 
Glasgow Coma Scale (GCS) score, pituitary dysfunction was 
detected in 16.8% of patients with mild TBI (GCS 13–15), 
10.9% with moderate TBI (GCS 9–12) and 35.5% with severe 
TBI (GCS 3–8).11
TBI patients with PTHP may suffer from a variety of clinical 
sequelae, including physical, psychological and cognitive deficits. 
Growth hormone (GH) deficiency, which is the most commonly 
reported endocrine dysfunction following TBI, has been linked 
to impaired quality of life, depression and poor rehabilitation 
outcome.12–14
risk factors
It is not known which groups of patients with TBI are more 
likely to develop pituitary dysfunction. Various factors have been 
implicated, but evidence is still lacking.
Severity of TBI
Several groups have suggested the severity of TBI, based on the 
admission GCS score, as a predictor of the development of PTHP 
(table 1).15–21 Kelly et al found that a GCS score of <10 was 
associated with PTHP.16 Similarly, in a sample of 104 patients, 
Klose et al reported that 81% of patients who developed PTHP 
had suffered severe TBI (GCS<9), whereas only 31% of those 
with normal pituitary function had a history of severe TBI.19 
A meta-analysis by Schneider and colleagues also demonstrated 
that the highest rate of PTHP (35.5%) occurred in patients with 
severe TBI, although the prevalence in moderate TBI (10.9%) 
was actually lower than that in mild TBI (16.8%).11 In contrast, 
other groups have found no correlation between post-traumatic 
pituitary dysfunction and the initial GCS score (table 1).22–27
Imaging findings
Kelly et al reported that certain imaging findings, such as diffuse 
brain swelling, on initial CT head scan predicted PTHP,16 while 
Schneider et al found an association between PTHP and diffuse 
axonal injury or basal skull fracture.26 However, two other 
studies failed to identify a convincing association between PTHP 
Types of evidence (adapted from agency for healthcare policy 
and research 1992)4
level evidence
Ia Evidence obtained from meta-analysis of randomised 
controlled trials
Ib Evidence obtained from at least one randomised 
controlled trial
IIa Evidence obtained from at least one well-designed 
controlled study without randomisation
IIb Evidence obtained from at least one other type of well-
designed quasi-experimental study
III Evidence obtained from well-designed non-
experimental descriptive studies, such as comparative 
studies, correlation studies and case–control studies
IV Evidence obtained from expert committee reports 
or opinions and/or clinical experience of respected 
authorities
grading of recommendations (adapted from agency for 
healthcare policy and research 1994)5
grade evidence levels Description
A Ia, Ib Requires at least one randomised 
controlled trial as part of the body of 
literature of overall good quality and 
consistency addressing the specific 
recommendation
B IIa, IIb, III Requires availability of well-conducted 
clinical studies but no randomised clinical 
trials on the topic of recommendation
C IV Requires evidence from expert committee 
reports or opinions and/or clinical 
experience of respected authorities.
Indicates absence of directly applicable 
studies of good quality
Table 1 Correlation between TBI severity (GCS score) and prevalence of PTHP
Study n gCS Time from injury Correlation between TBi severity and pThp
Hadjizacharia et al21 436 >12: 41.7%
9–12: 15.8%
<9: 42.4%
Mean 1.2 days Yes
Klose et al20 46 >12: 47.8%
9–12: 19.6%
<9: 32.6%
12 months Yes
Klose et al19 104 >12: 42.3%
9–12: 19.2%
<9: 39.4%
Median 13 months Yes
Bondanelli et al17 50 >12: 32%
9–12: 14%
<9: 54%
12–64 months Yes
Kelly et al16 22 3–15 Median 26 months Yes
Kozlowski Moreau et al27 55 Lowest GCS average: 8.8 >1 year No
Schneider et al26 70 3–15 12 months No
Aimaretti et al25 70 >12: 47.1%
9–12: 31.4%
<9: 21.4%
12 months No
Agha et al23 102 9–12: 44.1%
<9: 55.9%
Median 17 months No
Lieberman et al22 70 – Median 13 months No
GCS, Glasgow Coma Scale; PTHP, post-traumatic hypopituitarism; TBI, traumatic brain injury.
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and brain imaging findings, including intracranial haematomas 
and diffuse axonal injury.17 23
Other factors
Raised intracranial pressure (ICP) has been shown to be asso-
ciated with PTHP.28 29 Other factors implicated as predisposing 
to PTHP include hypotension and hypoxia,16 older age26 and 
prolonged intensive care unit stay.28 In contrast, possession of 
apolipoprotein E3/E3 genotype has been linked to a reduced risk 
of hypopituitarism following TBI.30
Blast TBI may be a particular risk factor for pituitary dysfunc-
tion.31 Thirty-two per cent of soldiers after moderate-severe 
blast TBI (defined according to the Mayo classification)32 devel-
oped anterior pituitary dysfunction, compared with 2.6% of 
age-matched and gender-matched civilians after moderate-severe 
non-blast TBI.31
pathophysiology
While the exact mechanisms underlying pituitary dysfunc-
tion have not been elucidated, several hypotheses have been 
proposed, with Dusick and colleagues concluding that it is likely 
the result of a combination of pathological processes.33
The most widely accepted theory is that of an ischaemic insult 
to the pituitary gland.33 34 TBI can be associated with direct 
damage to the hypophyseal portal veins,35 36 direct trauma to 
the gland37 38 or transection of the pituitary stalk.35 39 These, 
in association with the hypotension, hypoxia and brain swelling 
that frequently accompany TBI, lead to pituitary ischaemia and 
infarction.40 This is supported by postmortem findings in patients 
with TBI where the pathological features include capsular haem-
orrhage around the pituitary (59%), posterior lobe haemorrhage 
(31%), anterior lobe necrosis (22%) and stalk necrosis (3%).36 41 
In addition, a significant proportion of patients (42%) have been 
reported to manifest ischaemic/haemorrhagic lesions of the 
hypothalamus.37
Several other factors have also been implicated in the patho-
genesis of PTHP. The pituitary gland is susceptible to direct 
mechanical impact in TBI, particularly in those with a base 
of skull fracture. Acceleration/deceleration forces may cause 
shearing of white matter tracts connected to the pituitary gland. 
It has been suggested that GH and gonadotrophin deficiency are 
most commonly seen post-TBI due to the more laterally located 
somatotrophs and gonadotrophs.42 43
In vivo, imaging techniques in patients with moderate-to-se-
vere TBI have demonstrated pituitary enlargement in the 
acute phase.39 Over time, patients with TBI may exhibit loss 
of pituitary volume or an empty sella, abnormal enhancement, 
perfusion deficits and/or lack of the posterior pituitary signal.44 
Furthermore, 30% of patients show focal changes, including (1) 
haemorrhage/haemorrhagic infarction, (2) a swollen gland with 
bulging superior margin, (3) heterogeneous signal in the ante-
rior lobe and (4) partial transection of the infundibular stalk, 
following TBI.39 Soldiers after blast TBI who have pituitary 
dysfunction display more severe white matter tract damage as 
assessed by diffusion tensor imaging than those who have an 
intact hypothalamic–pituitary axis.31
Autoimmune-mediated pituitary dysfunction has also been 
postulated: higher titres of antipituitary (APAs) and antihypo-
thalamic (AHA) antibodies were detected in patients with TBI 
compared with controls at 3 and 5 years after the initial insult.45 46 
Boxers who suffer from chronic, repetitive insults to their brain 
also commonly have detectable circulating AHA (21.3%) and 
APA (22.9%). Furthermore, 46.2% of AHA-positive boxers have 
pituitary dysfunction, compared with just 10.4% in AHA-nega-
tive subjects.45 47
hypopituitarism
Anterior pituitary dysfunction
Acute phase
In the days following TBI, the prevalence of PTHP has been 
suggested to be as high as 53%–78% (table 2a). GH and gonad-
otrophins (luteinising hormone (LH) and follicle-stimulating 
hormone (FSH)) appear to be most commonly affected, and 
in the first 24 hours after TBI, approximately 20%–30% of 
patients were reported to manifest abnormalities in serum GH 
and insulin-like growth factor 1 (IGF-1) concentrations48 49; 
however, these observations were based on basal (non-dynamic) 
measurements, and therefore cannot be considered diagnostic 
of GH deficiency (GHD). Two recent studies have suggested 
high rates (52%–78%) of hypothalamic–pituitary–adrenal axis 
dysfunction within the first 10 days after injury, based on early 
morning (09:00) thresholds for (total) plasma/serum cortisol  of 
<276 nmol/L and <300 nmol/L, respectively.48 50 In a cohort of 
58 patients admitted to the neurocritical care unit following TBI, 
10.3% had abnormalities of the pituitary–adrenal axis within 
7 days.51 Accepting that the primary endocrine task in acute TBI 
is to identify those patients with acute hypocortisolism who are 
at risk of developing life-threatening complications (eg, inotro-
pe-resistant hypotension, hypoglycaemia and hyponatraemia), 
these findings would suggest a high rate of requirement for 
exogenous glucocorticoid therapy. However, it is noteworthy 
that while there was a clear association between acute hypoco-
rtisolism and mortality in the study of Hannon and colleagues, 
those individuals in the lowest quartile for plasma cortisol had 
Table 2a Prevalence of anterior hypopituitarism following TBI (<1 month)
Study n gCS
Time from 
injury
anterior hypopituitarism (axis affected)
Total (%) gh (%) fSh/lh (%) aCTh (%) TSh (%) multiple (%)
Alavi et al51 58 <14 0–7 days 10.3 – – 10.3 – –
Hannon et al50 100 <14 1–10 days 78 – – 78 – –
Olivecrona et al48* 45 <9 1 day – 30.2 55.2 52.3–54.5 9.1 –
4 days – 2.3 58.6 59.1–70.5 27.3 –
Krahulik et al66 186 3–14 Acute 53 37 33 10 3 –
Klose et al20 46 3–15 0–12 days 76 – 67 4 33 28
Tanriverdi et al49 52 3–15 24 hours 56 20 41 9.8 6 –
Agha et al52 50 8–13 Acute – 18 80 16 2 –
*Serum cortisol levels were measured in the morning and in the evening. 
ACTH, adrenocorticotropic hormone; FSH, follicle-stimulating hormone; GCS, Glasgow Coma Scale; GH, growth hormone; LH, luteinising hormone; TBI, traumatic brain injury; TSH, 
thyroid-stimulating hormone. 
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the highest mortality despite empirical treatment with hydrocor-
tisone. In addition, no patients in the study of Olivecrona et al 
were given glucocorticoids, and yet no association was observed 
between low cortisol levels and increased mortality or unfa-
vourable outcome.48 50 Accordingly, it remains unclear whether 
using simple numerical thresholds to diagnose hypoadrenalism 
in acute TBI facilitates earlier detection of potentially life-threat-
ening hypoadrenalism or leads to unnecessary glucocorticoid 
therapy.
It is also important to exercise caution when interpreting 
the results of endocrine testing during the acute phase of TBI 
because of the well-recognised hormonal changes that occur 
in normal subjects in response to acute intercurrent (non-en-
docrine) illness (eg, apparent central hypothyroidism due to 
non-thyroidal illness, for which there is little evidence of a role 
for thyroid hormone replacement therapy). It is conceivable 
therefore that at least some of the temporary hormone deficits 
noted in acutely ill patients, which resolve on follow-up testing, 
reflect a normal adaptive endocrine response rather than tran-
sient hypopituitarism.
Chronic phase
Disturbance of normal pituitary function appears to be tran-
sient in many patients, with rates of PTHP declining over 
time (tables 2a–c), although again with marked variation 
between studies (eg, 13%–56% at 3–6 months, 5.4%–76.4% 
at >12 months after TBI). Similarly, the extent of pituitary 
dysfunction differs markedly (tables 2a–c) and again reflects, 
at least in part, the variation in methodologies used and diag-
nostic tests employed. Nevertheless, GHD and hypogonado-
tropic hypogonadism remain the two most commonly identified 
endocrine deficits (similar to the acute phase), while most studies 
have found that <10% of patients manifest abnormalities of the 
ACTH-adrenal and thyroid-stimulating hormone (TSH)-thy-
roid axes in the longer term. Alavi et al found that of the 22 
patients assessed at >12 months following TBI, only two (9.1%) 
manifested GHD.51 One group who followed their patients at 
1 year, 3 years and 5 years post-TBI demonstrated a progressively 
decreasing trend for pituitary deficits from the first year to the 
fifth.46 In a study of 48 patients by Agha and colleagues, none 
of the 14 subjects who had normal anterior pituitary function 
when tested at 6 months, including dynamic endocrine tests, 
had developed PTHP at 12 months.52 Furthermore, 7 of the 34 
subjects who had pituitary dysfunction at 6 months had recov-
ered by 12 months.52 Recently, Cuesta et al identified symptoms 
of gonadal dysfunction as being the most reliable predictors 
of hypopituitarism in patients >6 months post-TBI, while in 
contrast non-specific symptoms were no more predictive than 
unselected screening.53
As already highlighted, much of the variation in prevalence 
rates can likely be attributed to differences in patient selection, 
investigations employed and thresholds applied to diagnose 
endocrine insufficiency.9 10 This is supported by the findings 
of a study that directly compared the use of different tests and 
cut-offs in determining the prevalence of post-traumatic GHD, 
and found significant discrepancies within the same individ-
uals.29 Specifically, the prevalence of GHD was lower when 
using local, compared with guideline-defined cut-offs, while 
insulin tolerance testing yielded a lower prevalence of GHD 
compared with the pyridostigmine-growth hormone-releasing 
hormone (PD-GHRH) or GHRH-arginine test.29
Posterior pituitary dysfunction
Posterior pituitary dysfunction following TBI is typically tran-
sient (<1 month duration). In the acute phase, the proportion 
of patients developing cranial diabetes insipidus (DI) again 
varies markedly between studies, ranging from 2.6% to 51% 
(table 3),21 50 54–57 and perhaps reflecting the inherent difficulties 
in establishing a firm diagnosis in the presence of confounding 
factors (eg, vigorous fluid resuscitation, use of hypertonic fluids, 
etc). Follow-up data indicate that few patients require long-term 
desmopressin therapy: Aimaretti et al reassessed 100 patients 
with TBI at 3 months’ postinjury and found that only 4% had 
DI24; at 6–9 months, 12 months and 17 months, the percent-
ages of patients with persistent DI were 1.4%–8%,57 58 6%57 
and 6.9%,55 respectively (table 3). Three studies have reported 
that the development of DI is associated with increased 
mortality.21 50 54
The syndrome of inappropriate antidiuretic hormone (SIADH) 
is also well recognised in the context of TBI. Hyponatraemia is 
most commonly seen within the first week after injury and may 
be multifactorial. The incidence of SIADH varies from 2.3% to 
36.6%, although recent studies suggest that between 1 in 7 and 
1 in 8 patients are affected.55 56 59 In most cases, it is a transient 
phenomenon: Agha et al found that of the 13 patients who had 
SIADH in the acute phase, only one persisted into the chronic 
phase.55
guiDaNCe
To screen all patients with TBI for pituitary dysfunction would 
represent a major logistical challenge and would likely yield 
Table 2b Prevalence of anterior hypopituitarism following TBI (<12 months)
Study n gCS
Time from 
injury
anterior hypopituitarism (axis affected)
Total (%) gh (%) fSh/lh (%) aCTh (%) TSh (%) multiple (%)
Abadi et al67 75 9–13 3 months 48 24 16 13 5.3 13
6 months – 9.3 10.7 4 2.7 –
Schneider et al68* 825 – <5 months 17–39 22 – – – –
Krahulik et al66 186 3–14 3 months 22.9 – – – – –
6 months 18.2 – – – – –
Klose et al20 46 3–15 3 months 13 – – – – 6.5
Schneider et al69 78 3–15 3 months 56 9 32 19 8 –
Agha et al56 48 8–13 6 months – 12.5 22.9 18.8 2.1 –
Aimaretti et al 24 100 3–15 3 months 35 37 17 8 5 –
*Patients were categorised into acute (<5 months) or chronic (>5 months) groups in this study.
ACTH, adrenocorticotropic hormone; FSH, follicle-stimulating hormone; GCS, Glasgow Coma Scale; GH, growth hormone; LH, luteinising hormone; TBI, traumatic brain injury; TSH, 
thyroid-stimulating hormone.
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false-positive results (especially in the acute phase due to phys-
iological changes associated with intercurrent illness), leading 
to unnecessary treatment in some patients. However, given the 
potentially serious clinical consequences of failing to diagnose 
hypopituitarism (especially hypoadrenalism), there is a pressing 
need to more reliably identify those patients with TBI who are 
at greatest risk.
anterior pituitary function testing during hospital admission
Some authors advise screening for hypocortisolism (relative or 
absolute) as soon as possible in all patients with clinical features 
and/or risk factors for acute adrenal insufficiency.60 61 Glynn 
and Agha have recommended that serum cortisol levels are 
monitored in the first 7 days post-TBI, so that glucocorticoid 
replacement can be initiated if there is any suspicion of gluco-
corticoid deficiency.10 For patients with mild TBI, Tanriverdi and 
colleagues proposed that screening for hypopituitarism (specif-
ically ACTH and TSH deficiency) should be undertaken if (1) 
the patient is expected to be hospitalised for >24 hours; (2) 
CT head shows an abnormality (brain swelling, diffuse axonal 
injury, basal skull fracture, epidural/subdural haematoma, cranial 
vault fractures); and (3) the patient manifests signs or symptoms 
of hypopituitarism.61 Most authors agree that acutely unwell 
patients with suspected hypoadrenalism should be treated 
urgently with parenteral high-dose glucocorticoids (see below). 
In contrast, in stable patients with central hypoadrenalism, lower 
dosages of oral hydrocortisone (15–25 mg/day) or prednisolone 
(2.5–5 mg/day) may suffice.50 62
However, as discussed above, given the challenges inherent in 
interpreting the results of endocrine tests in acutely ill patients, 
and the discordant findings in studies of cortisol replacement 
therapy based on numerical thresholds, we do not recommend 
routine testing of pituitary function or measurement of serum/
plasma cortisol levels in the acute phase after TBI. If there is a 
clinical suspicion of cortisol insufficiency, for example, hypoten-
sion (especially pressor-resistant) or hyponatraemia, empirical 
treatment with hydrocortisone 50mg 6–8 hourly, intravenously 
or intramuscularly; or 50–100mg as an initial intravenous bolus 
followed by an infusion of 4–8mg/hour should be given imme-
diately after taking a serum/plasma sample for random cortisol 
measurement. A discussion with the endocrinology team should 
follow within 24–48 hours. We recognise that some patients may 
be given glucocorticoid therapy for reasons other than suspected 
classical cortisol deficiency in the acute phase. Most of these 
Table 2c Prevalence of anterior hypopituitarism following TBI (≥12 months)
Study n gCS Time from injury
anterior hypopituitarism (axis affected)
Total (%) gh (%) fSh/lh (%) aCTh (%) TSh (%) multiple (%)
Alavi et al51 47 3–15 >6 months* 21.3 – 21.3 4.3 0 12.8
22 3–15 >12 months 9.1 9.1 – – – –
Kopczak et al70 340 – <1 month to 39 years 36.5 7.8 40 1.2 5.6 5.6
Hannon et al50 100 <14 Median 14 months 34.4 18.8 3.1 18.8 0 3.1
Tanriverdi et al46 25 3–15 1 year 48 44 8 16 4 16
3 years 23.5 23 0 0 0 0
5 years 32 28 4 1 0 1
Ulfarsson et al71 51 <9 2–10 years 27.5 21.6 3.9 0 2 –
Kozlowski Moreau 
et al27
55 Lowest GCS 
average 8.8
>1 year 76.4 63.6 3.6 27.3 21.8 –
Kokshoorn et al72 112 – Mean 4 years 5.4 2.7 0.9 1.8 – –
Schneider et al68† 825 – >5 months 37–38 – – – – –
Berg et al73 246 <13 Average 12 months 21 5 9 1 12 3
Krahulik et al66 186 3–14 12 months 21 13.5 5.6 – – –
Kleindienst et al74 71 3–15 24–36 months – 35 0 61 0 –
Wachter et al40 55 3–15 1–4 years 25.4 1.8 12.7 3.6 1.8 1.8
Tanriverdi et al75 30 3–15 1 year – 43.3 3.3 20 6.6 –
3 years – 23.3 0 6.6 0 –
Klose et al19 104 3–15 Median 13 months 15 15 2 5 2 3.8
Klose et al20 46 3–15 12 months 10.9 10.9 2.1 6.5 2.1 6.5
Herrmann et al76 76 <8 Median 20 months 24 8 17 2 2 6.6
Schneider et al69 78 3–15 12 months 36 10 20 9 3 4.3
Tanriverdi et al49 52 3–15 12 months 59 32 7.7 19 6 9.6
Leal-Cerro et al77 170 <8 >12 months 24.7 5.8 17 6.4 5.8 8.8
Aimaretti et al25 70 3–15 12 months 22.7 18.6 11.4 7.1 5.7 10.0
Agha et al23 102 3–13 Median 17 months 28 10.7 11.8 12.7 1 5.9
Agha et al52 50 8–13 12 months – 10.4 12.5 18.8 2.1 –
Bondanelli et al17 50 3–15 12–64 months 54 28 14 0 10 12
Popovic et al12 67 9–13 Median 44 months 34 15 9 7 4 10.4
Lieberman et al22 70 – Median 13 months 68.5 14.6 1.4 45.7 21.7 –
Kelly et al16 22 3–15 Median 26 months 36.4 18.2 22.7 4.5 4.5 –
*Patients were assessed at >6 months in this study.
†Patients were categorised into acute (<5 months) or chronic (>5 months) groups in this study.
ACTH, adrenocorticotropic hormone; FSH, follicle-stimulating hormone; GCS, Glasgow Coma Scale; GH, growth hormone; LH, luteinising hormone; TBI, traumatic brain injury; TSH, 
thyroid-stimulating hormone.
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patients will wean from therapy uneventfully, but where there 
is difficulty with withdrawing glucocorticoids we recommend 
assessment by an endocrinologist.
Recommendations
 ► Early (acute phase) testing for pituitary dysfunction is not 
recommended for the purpose of detecting post-TBI hypop-
ituitarism. (IV, C)
 ► Routine measurement of plasma/serum cortisol levels is not 
indicated in the acute phase following TBI. (IV, C)
 ► If there is clinical suspicion of cortisol insufficiency (eg, 
refractory hypotension, hypoglycaemia, hyponatraemia), 
immediately start empirical replacement with hydrocor-
tisone 50mg 6-8 hourly, intravenously or intramuscularly; 
or 50-100mg as an initial intravenous bolus followed by an 
infusion of 4-8mg/hour after taking a serum/plasma sample 
for random cortisol measurement, and discuss with endocri-
nology. (IV, C)
 ► If a patient is started on glucocorticoid therapy for reasons 
other than classical cortisol deficiency, and there is subse-
quent difficulty in withdrawing treatment, discuss with 
endocrinology. (IV, C) (figure 1)
posterior pituitary function testing during hospital admission
Cranial DI has been linked with increased mortality following 
TBI, and is a predictor of other long-term pituitary deficits.50 
Therefore, early recognition of cranial DI in patients with 
TBI displaying hypernatraemia and hypotonic polyuria is 
important.1 10 Tritos et al advise an on-demand approach to 
desmopressin replacement in this context, with careful moni-
toring of fluid balance and serum sodium levels, as DI is often 
transient.62
We recommend that if cranial DI is suspected, serum creatinine, 
electrolytes, plasma glucose and paired serum/plasma and urine 
osmolalities should be checked. Treatment with a single stat dose 
of desmopressin 0.5 μg subcutaneously should be given if there is 
unexplained polyuria and low urine osmolality. Early endocrine 
review is advised. Regular desmopressin orally or nasally may be 
required for a period of time. However, it is important to note 
that in patients with raised ICP, hypernatraemia may be a protec-
tive mechanism, and permissive hypernatraemia is sometimes 
used to treat intractable raised ICP, particularly in the intensive 
care setting. Thus, desmopressin should be used judiciously in 
patients with raised ICP.
SIADH may complicate TBI, and in the presence of hypo-
natraemia, water overload, cortisol insufficiency and hypo-
thyroidism should be considered as potential contributory 
factors. If there is suspicion of SIADH, euvolaemia should be 
confirmed, along with investigations to check paired serum/
plasma and urine osmolalities and urine sodium concen-
tration. Renal, adrenal and/or thyroid dysfunction should 
be excluded or corrected. An endocrinology review should 
follow. It is beyond the scope of this guidance to discuss the 
different strategies that may be required to diagnose and treat 
hyponatraemia, but the reader is directed to recently published 
comprehensive guidelines.63
Recommendations
 ► Cranial DI should be considered at an early stage in patients 
with TBI displaying hypernatraemia and hypotonic polyuria. 
(III, B)
 ► If cranial DI is suspected, check serum creatinine, electro-
lytes, plasma glucose and paired serum/plasma and urine 
osmolalities, give a stat dose of desmopressin 0.5 μg subcu-
taneously, and discuss with endocrinology. (IV, C)
 ► Although transient DI is recognised following TBI, some 
patients will need to be established on regular desmopressin 
(either orally or nasally) if there is unexplained polyuria and 
low urine osmolality, with subsequent reappraisal of ongoing 
long-term requirements by an endocrinologist. (IV, C)
 ► If SIADH is suspected in a patient with hyponatraemia, 
confirm euvolaemia, exclude/correct renal, adrenal and/or 
thyroid dysfunction, and check paired serum/plasma and 
urine osmolalities and urine sodium concentration, and 
discuss with endocrinology. (IV, C) (figure 1)
Screening for pituitary dysfunction following discharge from 
hospital
Although deficiencies in GH, FSH/LH and to a lesser extent 
TSH are likely to be of limited significance in the acute phase 
following TBI, in the longer term they may result in signif-
icant morbidity if left undiagnosed/untreated. Due to the 
potential confounding effects of non-thyroidal illness (sick 
euthyroid syndrome) and the long half-life of thyroxine, it 
has been suggested that screening for hypothalamic–pitu-
itary–thyroid dysfunction can reasonably be deferred for 
several (>4–6) weeks after TBI (assuming there is no suspi-
cion of prior thyroid dysfunction).50 62 Some authors recom-
mend screening for pituitary dysfunction at 3–6 months 
in all patients with moderate to severe TBI, using a combi-
nation of basal (non-stimulated) and, where appropriate, 
dynamic tests.1 10 11 64 65 Glynn and Agha have recommended 
screening for GH, gonadal, adrenal and thyroid dysfunction at 
3–6 months, and that any hormone deficiencies identified at 
this stage should be replaced, with a view to repeat assessment 
at 1 year.10
Based on the available evidence, anyone admitted for more 
than 48 hours for the management of TBI should undergo 
screening for pituitary dysfunction at 3–6 months using the 
tests shown in box 1. Patients with abnormal screening test 
results at 3–6 months should be referred to endocrinology for 
Table 3 Prevalence of posterior pituitary dysfunction following TBI
Study n gCS
Time from 
injury
% of posterior 
hypopituitarism 
(cranial diabetes 
insipidus)
<1 month
Hannon et al50 100 <14 Median 
6 days
51
Hadjizacharia et al21 436 3–15 Mean 
1.2 days
15
Agha et al57 50 <14 1–3 days 26
Agha et al55 102 <14 Acute 21.6
Agha et al56 50 <14 Median 
12 days
26
Boughey et al54 – – Mean 
1.5 days
2.9
>1 month
Bavisetty et al58 70 Median 7 6–9 months 1.4
Agha et al57 50 <14 6 months 8
12 months 6
Agha et al55 102 <14 Median 
17 months
6.9
Aimaretti et al24 100 3–15 3 months 4
GCS, Glasgow Coma Scale; TBI, traumatic brain injury.
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a full assessment that may include dynamic testing for GHD. 
Patients who are not admitted, or who are admitted for less 
than 48 hours, may require screening for pituitary dysfunction 
if they experience ongoing symptoms consistent with hypop-
ituitarism. These symptoms can include fatigue, low mood, 
poor motivation, reduced appetite, loss of libido,  sexual 
dysfunction (in men) and oligomenorrhoea/amenorrhoea (in 
women) (figure 2). Additionally, other causes of these symp-
toms should also be considered (including depression) and 
should be screened for using a standard brief screening tool 
such as the Hospital Anxiety and Depression (HAD) scale, 
Beck Depression Inventory II (BDI-II) or Patient Health Ques-
tionnaire (PHQ-9). It is important to bear in mind that there 
may be considerable overlap between the symptoms associated 
with TBI itself (particularly as a result of diffuse axonal injury) 
and those of pituitary dysfunction, which may exacerbate each 
other. Symptoms can therefore have a poor specificity for the 
presence of pituitary dysfunction.
If cortisol insufficiency (09:00 serum/plasma cortisol 
<100 nmol/L) is found, the patient should be started on oral 
hydrocortisone immediately (10 mg on waking, 5 mg at noon, 
5 mg at 17:00) and referred to endocrinology on an urgent 
basis. If the cortisol level is 100–400 nmol/L, a referral for 
further assessment should be made and the patient advised to 
follow ‘steroid sick day rules’ with emergency hydrocortisone 
cover until they have been reviewed by an endocrinologist. 
Referral to endocrinology for assessment of adrenal status is 
generally not required if the serum/plasma cortisol level is 
more than 400 nmol/L.
Note that while a serum/plasma IGF-I level below the refer-
ence range for age and gender is suggestive of GHD, it is not 
diagnostic, and requires referral to an endocrinologist for 
dynamic testing to investigate for GHD and coincident ACTH/
cortisol deficiency. Similarly, a serum/plasma IGF-I within the 
age-related reference range does not exclude GHD. However, 
referral for dynamic testing of GHD in a subject with an IGF-I 
level in the normal range can, in most instances, be deferred 
to >12 months after TBI, since GH replacement would gener-
ally not be considered until this time point as spontaneous 
recovery may occur in some subjects. If the patient remains 
symptomatic at this stage, then formal testing for GHD is 
indicated.
figure 1 Recommendations for screening for pituitary dysfunction in the acute phase of TBi. SiADH, syndrome of inappropriate antidiuretic hormone; TBi, 
traumatic brain injury.
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Recommendations
 ► Patients requiring admission for >48 hours following TBI 
should undergo screening at 3–6 months to exclude pituitary 
dysfunction (box 1). (IV, C)
 ► Patients with abnormal screening test results at 3–6 months 
or at 12 months should be referred to endocrinology for a 
full assessment. (IV, C)
 ► Patients not admitted, or admitted for less than 48 hours, 
but who have ongoing symptoms potentially consistent with 
pituitary dysfunction may warrant screening for pituitary 
dysfunction (box 1). (IV, C)
 ► Patients with ongoing symptoms of pituitary dysfunction (as 
above, box 1) should also be screened for depression using a 
standard brief screening tool such as the HAD scale, BDI-II 
or PHQ-9. (IV, C)
 ► The following ‘action limits’ for 09:00 serum/plasma cortisol 
are advised: <100 nmol/L, start treatment with oral hydro-
cortisone (10 mg on waking, 5 mg at noon and 5 mg at 17:00) 
immediately and refer urgently to endocrinology; 100-400 
nmol/L, refer to endocrinology and advise adherence to 
‘steroid sick day rules’ with emergency hydrocortisone cover 
(until review by endocrinology); >400 nmol/L, referral to 
endocrinology is not routinely required. (IV, C) (figure 3)
more than 1 year after TBi
Screening for GHD within a year of TBI is probably not neces-
sary as it may be temporary. However, patients with a history 
of TBI who continue to have or develop symptoms of possible 
hypopituitarism beyond 12 months should be referred to endo-
crinology for consideration of testing for GHD and other pitu-
itary dysfunction.
Recommendation
 ► Patients with a history of TBI who continue to display or 
develop symptoms of possible hypopituitarism beyond 
12 months should be referred to endocrinology for consider-
ation of testing for GH and other pituitary deficiencies. (III, 
B) (figure 3)
fuTure reSearCh
The many uncertainties surrounding PTHP are related to the 
relatively small number of studies in this area. Further research is 
warranted, and we believe the following areas deserve particular 
attention:
 ► What is the prevalence of pituitary dysfunction in mild TBI 
and persistent postconcussion syndrome?
 ► What is the prevalence of late-onset (>12 months) pituitary 
dysfunction post-TBI?
 ► Is there a demographic, clinical and/or imaging phenotype 
that reliably predicts those at particular risk of pituitary 
dysfunction?
 ► What is the hormone signature during the first 48 hours 
post-TBI?
 ► What are the pathophysiological mechanisms underlying 
pituitary dysfunction post-TBI?
 ► What is the impact of GH replacement on the quality of life 
and neurocognitive function after TBI in those who have 
GHD, and how does it relate to long-term sequelae?
Box 1 Screening for pituitary dysfunction post-traumatic 
brain injury (post-TBi)
The following tests (serum/plasma sample)* should be 
performed at 09:00:
men
Urea, creatinine and electrolytes
Free T4 and thyroid-stimulating hormone (TSH)
Cortisol
Luteinising hormone (LH), follicle-stimulating hormone (FSH), 
testosterone, sex hormone-binding globulin, albumin
Women
Urea, creatinine and electrolytes
Free T4 and TSH
Cortisol† and
in premenopausal women
If menstrual cycle has become abnormal post-TBI, check LH, FSH, 
oestradiol
in postmenopausal women
FSH
*If in doubt, check local laboratory requirements.
†If the patient is taking an oestrogen-containing oral contraceptive pill 
or oral hormone replacement therapy, we recommend seeking endocrine 
advice prior to assessing hypothalamic–pituitary–adrenal axis function.
figure 2 Symptoms suggestive of pituitary dysfunction.
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 ► What is the health economic analysis of pituitary function 
testing after TBI?
CoNCluSioN
There remain significant challenges in relation to the diag-
nosis, investigation and management of PTHP. First, TBI 
is common, and it would not be feasible (both on capacity 
and economic grounds), or indeed necessary (for the reasons 
outlined above), to perform endocrine testing in every patient 
with TBI. Despite the publication of several case series, the 
incidence of PTHP remains a matter of considerable debate 
with divergent rates reported between centres. In addition, 
although some data suggest that severe TBI is a particular risk 
factor for PTHP, even in this subgroup it is not clear which 
patients are at greatest risk and should be prioritised for inves-
tigation and treatment. The situation is further confounded 
by the considerable overlap in symptoms following TBI in 
patients with and without pituitary dysfunction. Finally, while 
single (static) blood tests may be used for screening purposes, 
the limitations of such an approach are well recognised, and 
definitive investigation frequently requires more complex 
dynamic hormone testing with interpretation by an experi-
enced endocrinologist.
We therefore recommend a pragmatic approach to screening 
for PTHP as set out above, but acknowledge there remains 
controversy surrounding whom to test, when to test and how 
to test. We suggest that there is an urgent need for a multicentre 
study powered to answer questions regarding the true incidence 
of PTHP, to determine the clinical and imaging parameters that 
predict which patients are at greatest risk, and to identify the 
optimal methods for, and timing(s) of, endocrine investigation.
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